About this trial
Tranexamic acid (TXA) is an effective hemostatic agent used to reduce blood loss and the need for transfusion. It is a relatively safe drug with minimal significant side effects. The most commonly reported complications include nausea, diarrhea, and occasional orthostatic reactions. The increased risk of thromboembolic events associated with the drug is the most serious complication; however, this has not been reported in most clinical studies and remains uncertain. Based on experience from other types of surgeries, tranexamic acid appears to be safe for use without an increased risk of venous thrombosis. To mitigate systemic absorption and minimize undesirable side effects, TXA can be applied topically rather than intravenously, reducing the risk of venous thromboembolism.
Eligibility criteria
Qualifiers
Indicated for the Extraction of Bilaterally Impacted Third Molars with Bone Retention.
Systemically healthy patients aged 14-40 years with no bleeding disorders.
Disqualifiers
Patients with systemic diseases affecting general health.
Patients diagnosed with any bleeding disorder.
Patients with advanced infection or cysts associated with the impacted tooth.
Trial design
Treatments tested in this trial
- Tranexamic acid
- saline irrigation